Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia
Completed · Phase 3
Conditions studied: Leukemia
In brief
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill acute myeloid leukemia cells. Histamine dihydrochloride may prolong remission and reduce the risk of relapse in patients with acute myeloid leukemia in remission. PURPOSE: Randomized phase III trial to determine the effectiveness of interleukin-2 plus histamine dihydrochloride in treating patients who have acute myeloid leukemia that is in remission following previous therapy.
Key facts
- Study ID
- NCT00003991
- Run by
- Maxim Pharmaceuticals
- People needed
- 360
- Starts
- 1998-07-01
- Expected to finish
- 2011-08-01
- Last updated by the study team
- 2013-11-06
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Arizona Cancer Center — Tucson, Arizona, United States
- Scripps Clinic — La Jolla, California, United States
- Cedars-Sinai Medical Center — Los Angeles, California, United States
- Kaiser Permanente-Southern California Permanente Medical Group — San Diego, California, United States
- Sidney Kimmel Cancer Center — San Diego, California, United States
- Pacific Hematology/Oncology — San Francisco, California, United States
- Bethesda Bone Marrow Stem Cell Transplant Institute — Boynton Beach, Florida, United States
- University of Florida Health Science Center - Jacksonville — Jacksonville, Florida, United States
- Emory University Hospital - Atlanta — Atlanta, Georgia, United States
- University of Kansas Medical Center — Kansas City, Kansas, United States
- Oncology and Hematology Associates — Westwood, Kansas, United States
- Maine Center for Cancer Medicine and Blood Disorders — Scarborough, Maine, United States
- Henry Ford Hospital — Detroit, Michigan, United States
- Providence Hospital Cancer Center — Southfield, Michigan, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Nevada Cancer Center — Las Vegas, Nevada, United States
- Nevada Medical Group-Internal Medicine — Reno, Nevada, United States
- University of New Mexico Cancer Research & Treatment Center — Albuquerque, New Mexico, United States
- New York Presbyterian Hospital - Cornell Campus — New York, New York, United States
- University of Rochester Cancer Center — Rochester, New York, United States
- Our Lady of Mercy Medical Center — The Bronx, New York, United States
- New York Medical College — Valhalla, New York, United States
- Ireland Cancer Center — Cleveland, Ohio, United States
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma, United States
- University of Alabama Comprehensive Cancer Center — Birmingham, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.